## Supplemental Table 1 Characteristics of selected studies.

| Author,               | Location | Design | No (I/C) | Age (I/C)<br>(year) | Operation                | Brand name of lipids | Duration<br>(day) | Dose<br>(day) | Control<br>group                                     | Time of<br>tested blood (day) | Adjustments   |
|-----------------------|----------|--------|----------|---------------------|--------------------------|----------------------|-------------------|---------------|--|-------------------------------|---|
| Zhu, 2013<br>[47]     | China    | RCT    | 33/33    | 48.62/51.52         | Liver<br>Transplantation | Omegaven             | 7                 | 2ml/kg        | PN without<br>supplementation o<br>ω-3 fatty acids   | 2<br>f                        | Age, sex, Child Pugh classification of<br>hepatic function, operation duration,<br>anhepatic phase, and postoperative<br>immunosuppression therapy                    |
| Wang, 2011<br>[49]    | China    | RCT    | 41/41    | 51.93/58.13         | Hepatectomy              | Omegaven             | 6                 | _             | Medium and Lon<br>Chain Fat Emulsio<br>Injection     |                               | Age, sex, Child-Pugh Score  |
| Tao, 2011<br>[50]     | China    | RCT    | 18/18    | 51.52/48.62         | Liver<br>Transplantation | Omegaven             | 6                 | 100ml         | ω-3/ω-6:<br>1/2 (I), 1/7 (C)                         | 2                             | Age, sex, BMI, MELD, Child-pugh score, etiology, operative time, blood lose   |
| Gong, 2016<br>[51]    | China    | RCT    | 59/60    | 51.37/49.63         | Hepatectomy              | Omegaven             | 5                 | 100ml         | regular nutrition<br>group (Kabiven)                 | 3                             | Age, gender, BMI, Child-pugh score, ICG<br>R15, pathology, resection range, blood<br>loss, Pringle time or surgery time   |
| Guo, 2018<br>[52]     | China    | RCT    | 15/15    | _                   | Hepatectomy              | Fresenius<br>Kabi    | 6                 | _             | Lipofundin (fat<br>emulsion; Braun,<br>Germany)      |                               | Age, sex, number of T-cell sub-types, cellular inflammatory factors and immunoglobulin  |
| Wu, 2012<br>[53]      | China    | RCT    | 31/32    | 52.00/52.16         | Hepatectomy              | Omegaven             | 5                 | 1.5 g/kg      | without omega-3 fatty acid suppleme                  |                               | Age, sex, diagnosis, warm ischemia time,<br>body mass index, liver function, blood loss<br>and duration of surgery  |
| Zhang, 2016<br>[54]   | China    | RCT    | 157/155  | 47.6/49.6           | Hepatectomy              | Omegaven             | 5                 | _             | ω-3/ω-6:<br>1/2 (I), 1/7 (C)                         | 3                             | Age, sex, weight, Child-Pugh Score, serum HBsAg and HBV-DNA status, FLR/SLV, serum biochemical parameters, Th/Ts, NRI after PN and associated therapy after admission |
| Ibrahim, 2016<br>[55] | Egypt    | RCT    | 20/20    | 30.20/31.00         | Liver<br>Transplantation | Fresenius<br>Kabi    | 2                 | 7 mL/kg       | the same infusion<br>rate of glucose 5% a<br>placebo |                               | Age, sex, BMI, graft (RT/LT lobe), fluid requirements, crystalloids, colloids, operative time   |

 $Abbreviations: I \ the \ intervention \ group, \ C \ the \ control \ group, \ \omega-3 \ \omega-3 \ polyunsaturated \ fatty \ acid, \ \omega-6 \ \omega-6 \ polyunsaturated \ fatty \ acid, \ MCT/LCT \ medium \ and \ long-chain \ triglycerides$